Description

What is Capmatinib? | Uses, Side Effects, and More

Capmatinib (brand name: Tabrecta) is a targeted cancer therapy used primarily in the treatment of non-small cell lung cancer (NSCLC). It is an oral medication developed to inhibit the MET (mesenchymal-epithelial transition) receptor tyrosine kinase, which is often abnormally activated in certain types of cancer.

How Capmatinib Works

Capmatinib is classified as a MET inhibitor. It works by blocking the activity of MET proteins that drive tumor growth in patients with specific MET exon 14 skipping mutations. By inhibiting this pathway, Capmatinib helps slow or stop the spread of cancer cells.

Approved Uses

Capmatinib is FDA-approved for the treatment of:

• Adult patients with metastatic NSCLC whose tumors have a MET exon 14 skipping alteration.

• It is used as a first-line therapy or in patients who have previously received other treatments.

Dosage and Administration

Capmatinib is taken orally, twice daily, with or without food. The typical dose is 400 mg twice daily, but it may be adjusted based on side effects or patient-specific factors.

Common Side Effects

Some of the most frequently reported side effects of Capmatinib include:

• Nausea

• Fatigue

• Vomiting

• Peripheral edema (swelling)

• Loss of appetite

• Diarrhea

• Elevated liver enzymes

Patients undergoing treatment with Capmatinib require regular liver function tests and may need dose adjustments if serious side effects occur.

Warnings and Precautions

Before starting Capmatinib, patients should inform their doctor about:

• Existing liver conditions

• Lung issues, especially interstitial lung disease

• Use of other medications that may interact

Capmatinib may cause interstitial lung disease (ILD) or pneumonitis, which can be life-threatening. Promptly report any symptoms like shortness of breath, cough, or fever to your healthcare provider.

Drug Interactions

Capmatinib may interact with:

• CYP3A inhibitors or inducers

• Certain antacids and acid-reducing agents
  Always disclose your full medication list to your healthcare provider.

Is Capmatinib Right for You?

Capmatinib is specifically designed for patients with a MET exon 14 skipping mutation, determined through a validated companion diagnostic test. If your cancer shows this genetic alteration, Capmatinib may offer a personalized treatment approach with targeted benefits.